MK-8527 and Rifampin for Untreated Latent Tuberculosis
Part of Immune system & allergy, Infections clinical trials.
This study tests whether a new medicine called MK-8527, combined with the antibiotic rifampin, can safely treat latent tuberculosis infection (a dormant TB infection that shows no symptoms). You may qualify if you have untreated latent TB but feel well otherwise.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with latent tuberculosis infection (dormant TB) that has never been treated
- You have no symptoms of active tuberculosis disease
- You have never received any tuberculosis or latent TB treatment before
- You are generally in good health aside from having latent TB
- You do not have hepatitis B, hepatitis C, or HIV
- You do not have a weakened immune system or conditions affecting major organs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
This trial tests a shorter, safer treatment for people with latent TB infection (TB germs in your body but not making you sick). The goal is to prevent you from getting sick with active TB later.
This trial studies whether taking rifapentine every day is safe and helps prevent active tuberculosis (TB) in people who have latent TB infection. It aims to find the best way to stop TB from becoming a serious illness later.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This study tests personalized TB treatment schedules based on your individual risk factors. Researchers want to see if matching treatment intensity to your specific situation helps cure TB while minimizing side effects.
Hear when a new HIV Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.